SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
JUNE 29, 2001
-------------
(Date of Report)
ENTROPIN, INC.
--------------
(Exact Name of Registrant as specified in its charter)
Colorado 33-23693 84-1090424
- ---------------------------- ----------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
45926 OASIS STREET, INDIO, CALIFORNIA 92201
-------------------------------------------
(Address of principal executive offices including zip code)
(760) 775-8333
---------------
(Registrant's telephone number including area code)
N/A
---
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS.
- ---------------------
Entropin, Inc. ("Entropin") issued the following press release on
June 27, 2001:
NEWS RELEASE
------------
ENTROPIN WEBCASTS 2001 ANNUAL MEETING OF SHAREHOLDERS PRESENTATION
INDIO, Calif. (June 27, 2001) - Entropin, Inc. (Nasdaq: ETOP, ETOPW), a
specialty pharmaceutical company developing new therapeutics for painful
soft tissue injuries and diseases, - today announced that its 2001 annual
meeting of shareholders presentation will be broadcast over the Internet on
June 28, 2001 at 1:00PM EDT with Tom Tachovsky, Ph.D., President and CEO of
Entropin.
What: Entropin 2001 Annual Meeting of Shareholders
When: 1:00PM EDT, June 28, 2001
Where: http://www.videonewswire.com/ENTROPIN/062801/
How: Over the Internet -- Simply log on to the web at the address
above
Contact: Zachary Bryant
Lippert/Heilshorn & Associates, Inc.
310-691-7100
The call will be archived for 30 days on the Web site www.entropin.com. To
access the replay, go to the "Investor Center" section and click on
Entropin 2001 Annual Meeting of Shareholders icon.
(Minimum Requirements to listen to broadcast: The RealPlayer software,
downloadable free from www.real.com/products/player/index.html, and at
least a 14.4Kbps connection to the Internet. If you experience problems
listening to the broadcast, send an email to webmaster@vdat.com.)
Entropin, Inc. is a pharmaceutical research and development company,
initially focused on the development of Esterom(R), a novel topical
therapeutic for the treatment of painful soft tissue injuries, such as
tendonitis or back sprain, that result in impaired function.
2
###
SIGNATURES
-----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: June 29, 2001 ENTROPIN, INC.
By /s/ Thomas G. Tachovsky
---------------------------------
Thomas G. Tachovsky
President and Chief Executive Officer
3